3/14
01:32 am
obio
Medium
Report
3/12
04:57 pm
obio
Orchestra BioMed (OBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $20.00 price target on the stock.
Medium
Report
Orchestra BioMed (OBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $20.00 price target on the stock.
3/12
08:38 am
obio
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update [Yahoo! Finance]
Medium
Report
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update [Yahoo! Finance]
3/12
08:17 am
obio
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Medium
Report
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
3/3
08:00 am
obio
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
Low
Report
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
2/19
08:00 am
obio
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Low
Report
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
2/13
04:05 pm
obio
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/22
06:43 am
obio
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) largest shareholders are retail investors with 41% ownership, institutions own 17% [Yahoo! Finance]
Low
Report
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) largest shareholders are retail investors with 41% ownership, institutions own 17% [Yahoo! Finance]
1/12
09:00 am
obio
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
Medium
Report
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
1/9
08:02 am
obio
Orchestra BioMed (NASDAQ:OBIO) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
Orchestra BioMed (NASDAQ:OBIO) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/31
11:21 am
obio
TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs [Yahoo! Finance]
Low
Report
TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs [Yahoo! Finance]